Diabetic Renal Disease in Patients with Type 2 Diabetes Mellitus
Tóm tắt
Over the last 35 years an increasing number of patients with type 2 diabetes mellitus have developed advanced renal disease and the need for dialysis. At present in the US, about 50% of the patients in dialysis units have type 2 diabetes mellitus. The explanation for the increase in the number of patients with type 2 diabetes mellitus in end-stage renal disease programs is not completely clear, but the overall number of patients with this type of diabetes is rapidly increasing — and is expected to continue to increase over the next years. The diagnosis of renal disease in type 2 diabetes mellitus is usually straightforward, and is mainly dependent upon measurements of urinary albumin or urinary protein excretion as well as serum creatinine measurements. Renal biopsies or exact glomerular filtration rate measurements are rarely necessary. Microalbuminuria is the first sign of renal disease in diabetes mellitus. It predicts overt nephropathy and cardiovascular disease. Several studies document that albuminuria and microalbuminuria can be reduced by treatment with antihypertensives, especially agents that block the renin angiotensin system. New studies show that end-stage renal disease can be postponed by the use of angiotensin II receptor antagonists. ACE inhibitors are also useful, and dual blockade of the renin angiotensin system has been utilized as well. However, generally speaking, patients with proteinuria have a poor prognosis. Screening for microalbuminuria is therefore proposed, and glycemic control and blood pressure should be optimized.
Tài liệu tham khảo
Ritz E, Rychlik I, editors. Nephropathy in type 2 diabetes. Oxford: Oxford Press, 1999
Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27(2): 167–94
Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type 1 and type 2 diabetes mellitus. Nephrol Dial Transplant 1994; 9: 1097–102
Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127–33
Hasslacher C, Ritz E, Wahl P, et al. Similar risks of nephropathy in patients with type 1 or type 2 diabetes mellitus. Nephrol Dial Transplant 1989; 4: 859–63
Schmitz R. Über die prognostische bedeutung und die atiologie der albuminurie bei diabetes. Berlin Klin Wschr 1891; 28: 373–7
Fahr T. Über atypische befunde aus den kapiteln des morbus brightii nebst anhangsweisen bemerkungen zur hypertoniefrage. Virchows Arch Path Anat 1924; 248: 323
Rayer P. Traité des maladies des reins et des alterations de la sécrétion urinaire étudiées en elles-mêmes et dans leurs rapports avec les maladies des uretères de la vessie, de la prostate et de l’urètre. Paris: Librairie de l’Académie Royale de Médecine, 1839
Ebstein W. Weiteres über diabetes, insbesondere über die complication desselben mit typhus abdominalis. Dtsch Arch Klin Med 1882; 30: 1
Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 1936; 12: 83–97
Fabre J, Balant LP, Dayer PG, et al. The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. Kidney Int 1982; 27: 167–94
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53
Vedel P, Obel J, Nielsen FS, et al. Glomerular hyperfiltration in microalbuminuric NIDDM patients. Diabetologia 1996; 39: 1584–9
Isomaa B, Henricsson M, Almgren P, et al. The metabolic syndrome influences the risk of chronic complications in patients with type 1 diabetes. Diabetologia 2001; 44: 1148–54
Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999; 353: 617–22
New JP, Marshall SM, Bilous RW. Renal auto-regulation is normal in newly diagnosed normotensive NIDDM patients. Diabetologia 1998; 41: 206–11
Valmadrid CT, Klein R, Moss SE, et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093–100
Gall MA, Hougaard P, Borch-Johnsen K, et al. Risk factors for the development of incipient and overt diabetic nephropathy in patients with non-insulin-dependent diabetes mellitus: prospective observational study. BMJ 1997; 314: 783–8
Mogensen CE. The kidney in diabetes: how to control renal and related cardiovascular complications. Am J Kidney Dis 2001; 37(1 Suppl. 2): S2–6
Olsen S, Mogensen CE. How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature. Diabetologia 1996; 39: 1638–45
Mogensen CE. Diabetic renal disease: the quest for normotension — and beyond. Diabet Med 1995; 12: 756–69
Bain SC, Chowdhury TA. Genetics of diabetic nephropathy and microalbuminuria. J R Soc Med 2000; 93: 62–6
Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. In: Mogensen CE, editor. The kidney and hypertension in diabetes mellitus. 5th ed. Boston (MA): Kluwer Academic Publishers, 2000: 655–706
Weir MR. Diabetes and hypertension: how low should you go and with which drugs? Am J Hypertens 2001; 14: 17S–26S
Adler AI, Stratton IM, Neil HAW, et al. on behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412–9
Gerstein HC, Mann JFE Qilong Y. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286: 421–6
Rachmani R, Levi Z, Lidar M, et al. Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract 2000; 49: 187–94
Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of ACE inhibition in NIDDM: a 7-year follow-up study. Arch Intern Med 1996; 156: 286–9
Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Ann Intern Med 1998; 128: 982–8
Olivarius Nd, Andreasen AH, Keiding N, et al. Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients: cross-sectional data from the population-based study ‘Diabetes Care in General Practice’, Denmark. Diabetologia 1993; 36: 1007–16
Ruggenenti P, Remuzzi G. Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol Dial Transplant 2000; 15: 1900–2
Vestra MD, Sailer A, Bortoloso E, et al. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 2000; 26Suppl. 4: 8–14
Dodson PM, Beevers M, Hallworth R. Sodium restriction and blood pressure in hypertensive type 2 diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ 1989; 298: 227–30
Nielsen S, Schmitz A, Rehling M, et al. The clinical course of renal function in NIDDM patients with normo- and microalbuminuria. J Intern Med 1997; 241: 133–41
Lam KSL, Cheng IKP, Janus ED, et al. Cholesterol lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604–9
Nielsen S, Schmitz O, Møller N, et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993; 36: 1079–86
Tonolo G, Ciccarese M, Brizzi P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric diabetic patients during long-term simvastatin treatment. Diabetes Care 1997; 20: 1891–5
Hommel E, Andersen P, Gall MA, et al. Plasma lipoproteins and renal function during simvastatin treatment in nephropathy. Diabetologia 1992; 35: 447–51
Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978; 1: 168–88
Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int 1997; 51: 1669–77
Christensen PK, Hansen HP, Parving HH. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int 1997; 52: 1369–74
Andersen NH, Mogensen CE. Inhibition of the renin-angiotensin system, with particular reference to dual blcokade treatment. J Renin Angio Aldo 2001 Sep; 2(3): 146–52
Cooper M, McNally PG, Boner G. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In: Mogensen CE, ed. The kidney and hypertension in diabetes mellitus. 5th ed. Boston: Kluwer Academic Publishers, 2000: 441–60
De Pablos PL, Martin FJM. Effects of losartan and diltiazem on blood pressure, insulin sensitivity, lipid profile and microalbuminuria in hypertensive type 2 diabetic patients. Clin Drug Invest 1998; 16: 361–70
Esmatjes E, Flores L, Inigo P, et al. Effect of losartan on TGF-β1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001; 16 Suppl. 1: 90–3
Lozano JV, Llisterri JL, Aznar J, et al. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16Suppl. 1: 85–9
Lacourcière Y, Bélanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58: 762–9
Foggensteiner L, Mulroy S, Firth J. Managment of diabetic nephropathy. J R Soc Med 2001; 94: 210–7
Mann JFE. Gerstein HC, Pogue J, et al., for the HOPE Investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE Randomized Trial. Ann Intern Med 2001; 134: 629–36
Mogensen CE, Neldam S, Tikkannen I, et al., for the CALM Study Group. Randomised controlled trial of dual blockade of the renin-angiotensin system in hypertensive, microalbuminuric, non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440–4
Parving HH, Lehnen H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med 2001; 345: 870–78
Muirhead N, Feagan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebocontrolled trial. Curr Ther Res 1999; 60: 650–60
Hermansen K. Diet, blood pressure and hypertension. Br J Nutr 2000; 83Suppl. 1: 113–9
Pijls LTJ, de Vries H, Donker AJ, et al. The effect of protein restriction on albu-minuria in patients with type 2 diabetes mellitus: a randomised trial. Nephrol Dial Transplant 1999; 14: 1445–53
Brenner BM, Cooper ME, de Zeeuw D, et al., for the Reduction of End-points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 395: 861–9
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60
Parving HH, Hovind P, Rossing K, et al. Evolving strategies for renoprotection: diabetic nephropy. Curr Opin Nephrol Hypertens 2001; 10: 515–22
Bergrem H, Leivestad T. Diabetic nephropathy and end-stage renal failure: the Norwegian story. Adv Ren Replace Ther 2001; 8: 4–12
Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001; 345: 910–1